GSKs Q4 Results Beat Market Estimate, sees 2024 Growth
Jan 31 Reuters GSK beat market estimates for fourthquarter profit and sales on Wednesday, underpinned by a strong launch of its respiratory syncytial virus RSV vaccine Arexvy and steady demand for its shingles shot and HIV medicines. The British drugmaker reported a profit of 28.9 pence per share on sales of 8.05 billion pounds 10.20 billion, […]